Giuffre Randall Michael

SEC source: 0001759822-26-000004 · form4-06032026_090625.xml · derivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,412

Underlying: Voting Common Shares · 40,412 shares

Expires 2036-06-01

F1 · derivative.exercise_date: Scheduled to vest in four equal quarterly installments.

SEC source: 0001759822-26-000002 · form4-01062026_100105.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,587

F1 · shares: Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $52,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026.

SEC source: 0001437749-25-019289 · rdgdoc.xml · derivative · entry 4

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,162

Underlying: Common Shares · 32,162 shares

Expires 2035-05-31

F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year.

SEC source: 0001235802-25-000009 · primary_doc.xml · derivative · entry 6

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 5,000 shares

Expires 2026-11-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option has fully vested.

SEC source: 0001235802-25-000009 · primary_doc.xml · derivative · entry 5

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 12,000 shares

Expires 2025-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option has fully vested.

SEC source: 0001235802-25-000009 · primary_doc.xml · nonDerivative · entry 2

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 392,412

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 95,016 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 128,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-25-000009 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 387,412

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 95,016 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 128,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-25-000004 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 375,412

F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $58,000. The deferred stock units will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025.

F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 95,016 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 111,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-24-000044 · primary_doc.xml · derivative · entry 4

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,472

Underlying: Common Shares · 28,472 shares

Expires 2034-05-31

F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year.

SEC source: 0001235802-24-000001 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 364,551

F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $53,750.

F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 84,155 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 111,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-23-000073 · primary_doc.xml · nonDerivative · entry 2

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,355

SEC source: 0001235802-23-000073 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,355

F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 64,959 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-23-000056 · primary_doc.xml · derivative · entry 4

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,968

Underlying: Common Shares · 16,968 shares

Expires 2033-05-31

F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year.

SEC source: 0001235802-23-000004 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295,355

F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $53,750.

F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 64,959 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-22-000135 · primary_doc.xml · nonDerivative · entry 2

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,225

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.41 to $1.44, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-22-000135 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,146

F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-22-000134 · primary_doc.xml · nonDerivative · entry 2

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,146

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.36 to $1.40, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 107,811 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-22-000134 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,572

F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 107,811 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-22-000128 · primary_doc.xml · nonDerivative · entry 3

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,453

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.20, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 82,118 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-22-000129 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 178,272

F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 82,937 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-22-000128 · primary_doc.xml · nonDerivative · entry 2

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,320

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.19, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 82,118 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-22-000128 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,350

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.19, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 82,118 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-22-000073 · primary_doc.xml · derivative · entry 5

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,222

Underlying: Common Shares · 13,222 shares

Expires 2032-05-31

F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year.

SEC source: 0001235802-22-000001 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,225

F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $53,750.

F2 · balance_after: Amount reflects the cancellation of 422 shares underlying deferred share units granted in lieu of Board committee retainers due to a change in Board committee memberships.

F3 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 14,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-21-000082 · primary_doc.xml · derivative · entry 5

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,393

Underlying: Common Shares · 9,393 shares

Expires 2031-07-14

F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year.

SEC source: 0001235802-21-000003 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,029

F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $61,250.

F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 15,225 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 36,498 voting common shares held by Michael Giuffre and his wife jointly and 60,160 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-20-000138 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,588

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.249 to $4.283, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 7,784 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 36,498 voting common shares held by Michael Giuffre and his wife jointly and 60,160 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-20-000051 · primary_doc.xml · derivative · entry 5

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,306

Underlying: Common Shares · 13,306 shares

Expires 2030-05-31

F4 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year.

SEC source: 0001235802-20-000051 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,588

F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $35,729.

F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 36,498 voting common shares held by Michael Giuffre and his wife jointly and 45,160 voting common shares held by Michael Giuffre individually.

SEC source: 0001235802-19-000061 · primary_doc.xml · derivative · entry 5

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,950

Underlying: Common Shares · 12,950 shares

Expires 2029-06-23

F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year.

SEC source: 0001235802-18-000179 · primary_doc.xml · nonDerivative · entry 1

Giuffre Randall Michael · CIK 0001759822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,804

F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 36,498 voting common shares held by Michael Giuffre and his wife jointly and 45,160 voting common shares held by Michael Giuffre individually.